BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9934485)

  • 1. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
    Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.
    Baker CT; Salituro FG; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3631-6. PubMed ID: 9934484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
    Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
    Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
    Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
    Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Schiffer CA; Rana TM
    J Med Chem; 2010 Nov; 53(21):7699-708. PubMed ID: 20958050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and clinical development of HIV-1 protease inhibitors.
    Huff JR; Kahn J
    Adv Protein Chem; 2001; 56():213-51. PubMed ID: 11329855
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
    Lu Z; Raghavan S; Bohn J; Charest M; Stahlhut MW; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2003 May; 13(10):1821-4. PubMed ID: 12729673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
    Tyndall JD; Reid RC; Tyssen DP; Jardine DK; Todd B; Passmore M; March DR; Pattenden LK; Bergman DA; Alewood D; Hu SH; Alewood PF; Birch CJ; Martin JL; Fairlie DP
    J Med Chem; 2000 Sep; 43(19):3495-504. PubMed ID: 11000004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
    Rocheblave L; Bihel F; De Michelis C; Priem G; Courcambeck J; Bonnet B; Chermann JC; Kraus JL
    J Med Chem; 2002 Jul; 45(15):3321-4. PubMed ID: 12109915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
    Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
    ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel isopropanolamine derivatives as non-peptide human immunodeficiency virus protease inhibitors.
    Zhou L; Yang Q; Wang Y; Hu Y; Luo X; Bai D; Li S
    Chem Pharm Bull (Tokyo); 2008 Aug; 56(8):1147-52. PubMed ID: 18670116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of anti-HIV double-drugs. conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor through spontaneously cleavable linkers.
    Matsumoto H; Kimura T; Hamawaki T; Kumagai A; Goto T; Sano K; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2001 Jun; 9(6):1589-600. PubMed ID: 11408178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.